

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2291)

INSIDE INFORMATION POSITIVE PROFIT ALERT

This announcement is made by LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the review of the Group’s preliminary unaudited consolidated management accounts for the six months ended June 30, 2024 (the “**Reporting Period**”), the Group is expected to record a net profit attributable to owners of the Company ranging from approximately RMB120 million to approximately RMB150 million, which increased approximately 57.69% to 97.11% as compared that of RMB76.1 million for the six months ended June 30, 2023. It is estimated that the non-IFRS profit is ranging from approximately RMB130 million to approximately RMB160 million, which increased approximately 50.29% to 84.97% as compared with that of approximately RMB86.5 million for the six months ended June 30, 2023.

Based on currently available information, the expected increase in net profit attributable to the Shareholders was mainly due to the followings:

- (1) Since obtaining the registration certificate from the National Medical Products Administration in September 2023, the Group’s innovative product, MemoSorb® Biodegradable patent foramen ovale occluder, has garnered high attention and enthusiastic reception from numerous patients due to its degradable technology. The product achieved rapid commercialization during the Reporting Period, thereby significantly increasing the Group’s revenue. This growth benefited from the Group’s forward-looking research and development strategy, strong marketing capabilities, effective academic promotion, and well-established distribution network; and
- (2) the Group’s commercialization strategy for each of its innovative products is effectively implemented and has received positive results. The MemoCarna® generation III congenital heart disease occluders, which are oxide coating occluders, have further increased the penetration rate in the PRC market. Sales performance of these products showed a significant improvement during the Reporting Period compared to the six months ended June 30, 2023.

The Company believes that the Group will not only maintain but also expand its robust business performance, aiming to deliver even better returns to the Shareholders in 2024.

As the Group's consolidated financial results for the Reporting Period has not yet been finalised and unaudited, the information contained in this announcement is based on information that is currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period which have not yet been reviewed by the Company's audit committee. The actual interim financial results of the Group for the Reporting Period, which may be subject to adjustment(s) and which may differ from the information contained in this announcement, are expected to be published before the end of August 2024.

The Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
July 5, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan as an executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Liu Daozhi as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*